The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
Elizabeth Robins Gerstner
No relevant relationships to disclose
Mike Levine
No relevant relationships to disclose
Xiaobu Ye
No relevant relationships to disclose
Tom Mikkelsen
No relevant relationships to disclose
Louis B. Nabors
No relevant relationships to disclose
Jeffrey J. Olson
No relevant relationships to disclose
Thomas Joseph Kaley
No relevant relationships to disclose
Patrick Y. Wen
Research Funding - AstraZeneca
Tracy Batchelor
Consultant or Advisory Role - Advanced Medical; Champions Biotechnology; Kyowa Hakko Kirin; Merck; Roche; Spectrum Pharmaceuticals
Honoraria - American Society of Hematology; Educational Concepts Group; Oakstone Medical Publishing; Research to Practice; Robert Michael Educational Institute LLC; UpToDate
Research Funding - AstraZeneca; Millennium; Pfizer
Stuart A. Grossman
No relevant relationships to disclose